A Phase 1 interventional study of PF-06882961 followed by PF-06882961/PF-06865571 and PF-06882961/PF-06865571 followed by PF-06882961 in Healthy Volunteer, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants. Part B will evaluate the effect of PF-06882961 on the PK of PF-06865571, as well as the effect of PF-06865571 on the PK of PF-06882961 in overweight adults or adults with obesity who are otherwise healthy.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female participants must be 18 to 65 years of age, inclusive, at the time of signing the ICD.
Women can be of , however, cannot be pregnant, breastfeeding, or planning to become pregnant while participating in the study.
and total body weight:
Part A: BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb); Part B: BMI ≥25 kg/m2 and not more than 40 kg/m2 at Screening; stable body weight, defined as \<5 kg change (per participant report) for 90 days before Screening.
Exclusion Criteria
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary: ≥6.5%. or ALT > . Total level > ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and are eligible for this study provided the direct bilirubin level is ≤ ULN.
TSH > ULN or \< LLN. Serum calcitonin > ULN. Amylase or lipase > ULN. Fasting blood glucose ≥126 mg/dL. Fasting triglycerides >200 mg/dL. > ULN. \< LLN. \<80 mL/min/1.73 m2 as calculated by the CKD-EPI equation. Positive testing for HIV, HepBsAg, or HCVAb. Study participants positive for HCVAb are to be excluded unless known to have been treated with a known curative therapy and negative for . Hepatitis B vaccination is allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A - PF-06882961 single dose followed by Treatment B - PF-06882961 single dose and PF-06865571 single dose
Drug: PF-06882961 followed by PF-06882961/PF-06865571
Treatment B - PF-06882961 single dose and PF-06865571 single dose followed by Treatment A - PF-06882961 single dose
Drug: PF-06882961/PF-06865571 followed by PF-06882961
Period 1: PF-06865571 single dose, Period 2: PF-06882961 twice daily dose titration, Period 3: PF-06865571 single dose and PF-06882961 twice daily dosing, Period 4: PF-06865571 twice daily dosing and PF-06882961 twice daily dosing
Drug: PF-06882961 + PF-06865571
Drug pages: Danuglipron · Ervogastat
Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
Drug pages: Danuglipron · Ervogastat
Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
Drug pages: Danuglipron · Ervogastat
Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
Part A: PF-06882961 Maximum Observed Concentration (Cmax)
Cmax for PF-06882961 was observed directly from data.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1
Part A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24)
AUC24 for PF-06882961 was determined by Linear/Log trapezoidal method.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1
Part B: PF-06865571 Cmax on Day 1 and Day 47
Cmax for PF-06865571 was observed directly from data on Day 1 and Day 47.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose
Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 47
AUClast for PF-06865571 was determined by Linear/Log trapezoidal method on Day 1 and Day 47.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose
Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 47
AUCinf for PF-06865571 was calculated as AUClast + (Clast\*/kel) on Day 1 and Day 47. Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the elimination rate constant.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose
Part B: PF-06882961 Cmax on Day 46 and Day 61
Cmax for PF-06882961 was observed directly from data on Day 46 and Day 61.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
Part B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 61
AUC 12 for PF-06882961 was determined by Linear/Log trapezoidal method on Day 46 and Day 61.
Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Part A
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.
Time frame: Up to 68 days
Number of Participants With Clinical Laboratory Abnormalities in Part A
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.
Time frame: From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part A
Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from baseline (BL) of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.
Time frame: From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days
Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria in Part A
ECG assessments included pulse rate (PR), QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or baseline (BL) \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.
Time frame: From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days
Number of Participants With TEAEs in Part B
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.
Time frame: Up to 173 days
Number of Participants With Clinical Laboratory Abnormalities in Part B
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.
Time frame: From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part B
Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from BL of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.
Time frame: From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days
Change From Baseline in Body Weight for Participants in Part B
Changes from baseline in body weight of the participants were measured.
Time frame: At Baseline (Days -28 to 2), on Period 2, Days 6, 13, 20 ,27, 34, and 41, Period 4, Days 9 and14 and follow-up visit (Days 68-71)
Number of Participants With ECG Data Meeting Pre-specified Criteria in Part B
ECG assessments included PR, QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or BL \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.
Time frame: From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days
Number of Participants With Suicidal Ideation or Behavior as Per C-SSRS Mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) in Part B
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
Time frame: At Screening (Days -28 to -2), Baseline (Period 1 Day -1), on Period 2, Days 6, 13, 20, 27, 34 and 41, Period 4, Days 2, 9 and 14 and follow-up visit (Days 68-71)
Number of Participants With Response to PHQ-9 in Part B
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). Any participant with a response of any scale other than "not at all" to any of the 9 questions was counted.
Time frame: At Screening (Days -28 to -2), Baseline (Period 1 Day -1), on Period 2, Days 6, 13, 20, 27, 34 and 41, Period 4, Days 2, 9 and 14 and follow-up visit (Days 68-71)
A total of 8 participants were enrolled in Part A of the study and 19 participants were enrolled in Part B of the study.
| Milestone | Part A Sequence 1 | Part A Sequence 2 | Part B |
|---|---|---|---|
| Started | 4 | 4 | 19 |
| Received treatment | 4 | 4 | 19 |
| Completed | 4 | 4 | 16 |
| Not completed | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Withdrawal by participant | 0 | 0 | 1 |
Cmax for PF-06882961 was observed directly from data.
| nanogram per milliliter (ng/mL) | PF-06882961 20 mg | PF-06882961 20 mg + PF-06865571 300 mg |
|---|---|---|
| Part A: PF-06882961 Maximum Observed Concentration (Cmax) | 15.69 ± 198 | 17.09 ± 265 |
AUC24 for PF-06882961 was determined by Linear/Log trapezoidal method.
| nanogram*hour per milliliter (ng.hr/mL) | PF-06882961 20 mg | PF-06892961 20 mg + PF-06865571 300 mg |
|---|---|---|
| Part A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24) | 109.5 ± 198 | 123.9 ± 311 |
Cmax for PF-06865571 was observed directly from data on Day 1 and Day 47.
| ng/mL | Day 1 (PF-06865571 300 mg) | Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID) |
|---|---|---|
| Part B: PF-06865571 Cmax on Day 1 and Day 47 | 2078 ± 37 | 791 ± 41 |
AUClast for PF-06865571 was determined by Linear/Log trapezoidal method on Day 1 and Day 47.
| ng*hr/mL | Day 1 (PF-06865571 300 mg) | Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID) |
|---|---|---|
| Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 47 | 9011 ± 38 | 6630 ± 40 |
AUCinf for PF-06865571 was calculated as AUClast + (Clast\*/kel) on Day 1 and Day 47. Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the elimination rate constant.
| ng*hr/mL | Day 1 (PF-06865571 300 mg) | Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID) |
|---|---|---|
| Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 47 | 9029 ± 38 | 6726 ± 43 |
Cmax for PF-06882961 was observed directly from data on Day 46 and Day 61.
| ng/mL | Day 46 (PF-06882961 Titration up to 200 mg BID) | Day 61 (PF-06865571 300 mg BID + PF-06882961 200 mg BID) |
|---|---|---|
| Part B: PF-06882961 Cmax on Day 46 and Day 61 | 1187 ± 115 | 1393 ± 107 |
AUC 12 for PF-06882961 was determined by Linear/Log trapezoidal method on Day 46 and Day 61.
| ng.hr/mL | Day 46 (PF-06882961 Titration up to 200 mg BID) | Day 61 (PF-06865571 300 mg BID + PF-06882961 200 mg BID) |
|---|---|---|
| Part B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 61 | 7682 ± 99 | 9312 ± 99 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.
| Participants | PF-06882961 20 mg | PF-06882961 20 mg + PF-06865571 300 mg |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Part A | 0 | 0 |
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.
| Participants | PF-06882961 20 mg | PF-06882961 20 mg + PF-06865571 300 mg |
|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities in Part A | 2 | 3 |
Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from baseline (BL) of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.
| Participants | PF-06882961 20 mg | PF-06882961 20 mg + PF-06865571 300 mg |
|---|---|---|
| Supine systolic BP value <90mmHg | 0 | 0 |
| Supine systolic BP change >=30mmHg increase | 0 | 0 |
| Supine systolic BP change >=30mmHg decrease | 0 | 1 |
| Supine diastolic BP value <50mmHg | 0 | 0 |
| Supine diastolic BP change >=20mmHg increase | 0 | 0 |
| Supine diastolic BP change >=20mmHg decrease | 0 | 0 |
| Pulse rate value <40bpm | 0 | 0 |
| Pulse rate value >120bpm | 0 | 0 |
ECG assessments included pulse rate (PR), QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or baseline (BL) \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.
| Participants | PF-06882961 20 mg | PF-06882961 20 mg + PF-06865571 300 mg |
|---|---|---|
| PR interval value >= 300 msec | 0 | 0 |
| PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 | 0 |
| QRS interval value>=140 msec | 0 | 0 |
| QRS interval %change >=50% | 0 | 0 |
| QTcF value >450 and <=480 msec | 0 | 0 |
| QTcF value >480 and <=500 msec | 0 | 0 |
| QTcF value >500 msec | 0 | 0 |
| QTcF change >30 and <=60 msec | 0 | 0 |
| QTcF change >60 msec | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.
| Participants | PF-06865571 300 mg | PF-06882961 Titration up to 200 mg BID | PF-06865571 300 mg + PF-06882961 200 mg BID | PF-06865571 300 mg BID + PF-06882961 200 mg BID |
|---|---|---|---|---|
| All-causality TEAEs | 1 | 18 | 6 | 10 |
| Treatment-related TEAEs | 1 | 16 | 6 | 10 |
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.
| Participants | PF-06865571 300 mg | PF-06882961 Titration up to 200 mg BID | PF-06865571 300 mg + PF-06882961 200 mg BID | PF-06865571 300 mg BID + PF-06882961 200 mg BID |
|---|---|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities in Part B | 0 | 16 | 0 | 15 |
Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from BL of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.
| Participants | PF-06865571 300 mg | PF-06882961 Titration up to 200 mg BID | PF-06865571 300 mg + PF-06882961 200 mg BID | PF-06865571 300 mg BID + PF-06882961 200 mg BID |
|---|---|---|---|---|
| Supine systolic BP value <90mmHg | 0 | 0 | 0 | 0 |
| Supine systolic BP change >=30mmHg increase | 0 | 0 | 0 | 0 |
| Supine systolic BP change >=30mmHg decrease | 0 | 0 | 0 | 0 |
| Supine diastolic BP value <50mmHg | 0 | 0 | 0 | 0 |
| Supine diastolic BP change >=20mmHg increase | 0 | 1 | 0 | 1 |
| Supine diastolic BP change >=20mmHg decrease | 0 | 0 | 0 | 0 |
| Pulse rate value <40bpm | 0 | 0 | 0 | 0 |
| Pulse rate value >120bpm | 0 | 0 | 0 | 0 |
Changes from baseline in body weight of the participants were measured.
| kilogram (kg) | All Participants |
|---|---|
| Period 2 Day 6 | -0.73 ± 1.999 |
| Period 2 Day 13 | -1.49 ± 2.260 |
| Period 2 Day 20 | -2.48 ± 2.242 |
| Period 2 Day 27 | -3.32 ± 2.525 |
| Period 2 Day 34 | -4.76 ± 3.141 |
| Period 2 Day 41 | -5.39 ± 2.599 |
| Period 4 Day 2 | -6.09 ± 3.088 |
| Period 4 Day 9 | -6.89 ± 3.299 |
| Period 4 Day 14 | -6.93 ± 3.632 |
| Follow-up | -4.59 ± 3.916 |
ECG assessments included PR, QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or BL \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.
| Participants | PF-06882961 Titration up to 200 mg BID | PF-06865571 300 mg BID + PF-06882961 200 mg BID |
|---|---|---|
| PR interval value>=300 msec | 0 | 1 |
| PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase) | 0 | 0 |
| QRS interval value>=140 msec | 0 | 0 |
| QRS interval %change >=50% | 0 | 0 |
| QTcF value >450 and <=480 msec | 0 | 0 |
| QTcF value >480 and <=500 msec | 0 | 0 |
| QTcF value >500 msec | 0 | 0 |
| QTcF change >30 and <=60 msec | 0 | 0 |
| QTcF change >60 msec | 0 | 0 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
| Participants | All Participants |
|---|---|
| Baseline | 0 |
| Period 2 Day 6 | 0 |
| Period 2 Day 13 | 0 |
| Period 2 Day 20 | 0 |
| Period 2 Day 27 | 0 |
| Period 2 Day 34 | 0 |
| Period 2 Day 41 | 0 |
| Period 4 Day 2 | 0 |
| Period 4 Day 9 | 0 |
| Period 4 Day 14 | 0 |
| Follow-up | 0 |
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). Any participant with a response of any scale other than "not at all" to any of the 9 questions was counted.
| Participants | All Participants |
|---|---|
| Baseline | 2 |
| Period 2 Day 6 | 0 |
| Period 2 Day 13 | 0 |
| Period 2 Day 20 | 0 |
| Period 2 Day 27 | 0 |
| Period 2 Day 34 | 0 |
| Period 2 Day 41 | 0 |
| Period 4 Day 2 | 0 |
| Period 4 Day 9 | 0 |
| Period 4 Day 14 | 0 |
| Follow-up | 0 |
Collected over Up to 68 days for Part A and up to 173 days for Part B.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06882961 20 mg | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| PF-06882961 20 mg + PF-06865571 300 mg | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| PF-06865571 300 mg | 0/19 (0%) | 0/19 (0%) | 1/19 (5.3%) |
| PF-06882961 Titration up to 200 mg BID | 0/19 (0%) | 0/19 (0%) | 18/19 (94.7%) |
| PF-06865571 300 mg + PF-06882961 200 mg BID | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| PF-06865571 300 mg BID + PF-06882961 200 mg BID | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Event | PF-06882961 20 mg | PF-06882961 20 mg + PF-06865571 300 mg | PF-06865571 300 mg | PF-06882961 Titration up to 200 mg BID | PF-06865571 300 mg + PF-06882961 200 mg BID | PF-06865571 300 mg BID + PF-06882961 200 mg BID |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/8 | 0/8 | 1/19 | 12/19 | 1/16 | 6/16 |
| Decreased appetiteMetabolism and nutrition disorders | 0/8 | 0/8 | 0/19 | 10/19 | 0/16 | 0/16 |
| DyspepsiaGastrointestinal disorders | 0/8 | 0/8 | 0/19 | 8/19 | 0/16 | 2/16 |
| SomnolenceNervous system disorders | 0/8 | 0/8 | 0/19 | 8/19 | 0/16 | 1/16 |
| VomitingGastrointestinal disorders | 0/8 | 0/8 | 0/19 | 7/19 | 3/16 | 6/16 |
| ConstipationGastrointestinal disorders | 0/8 | 0/8 | 0/19 | 6/19 | 1/16 | 0/16 |
| HeadacheNervous system disorders | 0/8 | 0/8 | 0/19 | 4/19 | 1/16 | 4/16 |
| Abdominal discomfortGastrointestinal disorders | 0/8 | 0/8 | 0/19 | 3/19 | 1/16 | 2/16 |
| Abdominal distensionGastrointestinal disorders | 0/8 | 0/8 | 0/19 | 3/19 | 0/16 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/8 | 0/19 | 3/19 | 0/16 | 1/16 |
| Age, Customized(Participants) | Part A Sequence 1 | Part A Sequence 2 | Part B | Total |
|---|---|---|---|---|
| 18-44 Years | 3 | 3 | 7 | 13 |
| 45-64 Years | 1 | 1 | 12 | 14 |
| >=65 Years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A Sequence 1 | Part A Sequence 2 | Part B | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 1 | 3 |
| Male | 3 | 3 | 18 | 24 |
| Race/Ethnicity, Customized(Participants) | Part A Sequence 1 | Part A Sequence 2 | Part B | Total |
|---|---|---|---|---|
| White | 2 | 1 | 15 | 18 |
| Black or African American | 2 | 3 | 4 | 9 |
| Race/Ethnicity, Customized(Participants) | Part A Sequence 1 | Part A Sequence 2 | Part B | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 5 | 7 |
| Not Hispanic or Latino | 3 | 3 | 14 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Apr 2021 to primary completion in Oct 2021, 6 months.
Results were first posted in Aug 2023, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Danuglipron · Ervogastat